<DOC>
	<DOCNO>NCT01238107</DOCNO>
	<brief_summary>A phase II clinical study evaluate MT-102 administer sixteen week period subject cachexia relate non-small cell lung cancer colorectal cancer</brief_summary>
	<brief_title>A Clinical Study With MT-102 Subjects With Cancer Cachexia</brief_title>
	<detailed_description>Cachexia waste disease , associate significant morbidity mortality , accompany wide range serious illness , currently widely approve therapeutic agent . Cachexia define weight loss , associate chronic underlying disease , least 5 % 12 month less . It associate fatigue , loss muscle strength , low fat free index neurohormonal biochemical abnormality . Cancer cachexia occur third patient cancer estimate direct cause death 20 % cancer relate death . As solid tumour , colorectal cancer ( CRC ) non-small cell lung cancer ( NSCLC ) relatively high incidence cachexia , approximately 28 % 34 % respectively.Through combine pharmacological action , MT-102 multi-functional effect upon three potential pharmacological target , relevant cancer cachexia</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<criteria>1 . Adult patient age 25 80 year age life expectancy great 3 month judge treat physician . 2 . Confirmed diagnosis one : a. Noncurative stage III stage IV Colorectal Cancer ( CRC ) suitable surgery , b. Noncurative stage III stage IV Nonsmall Cell Lung Cancer ( NSCLC ) suitable surgery ; 3 . Patients receive already receive course chemotherapy , without radiotherapy surgery , one follow regime : . For nonsmall cell lung cancer , platinum base regimen b . For colorectal cancer , 5FU Irinotecan base regimen 4 . Cachexia ongoing weight loss opinion investigator due underlying cancer . 5 . Evidence cachexia judge one : . ≥5 % documented weight loss previous 12 month ; b . A subjective report weight loss previous 12 month record body mass index ( BMI ) less 20.0 kg/m2 c. Ongoing document weight loss least 1kg week prior day 0 ; 1.25kg 2 week prior day 0 , 1.5kg 3 6 week prior day 0 ; provide BMI 25 . 6 . At least two follow : a. Subjective report decrease muscle strength b. Subjective report fatigue c. Subjective report anorexia d. Abnormal biochemistry one following : i. CRP &gt; ULN ( per Central Lab normal value ) ii . Anemia ( &lt; 12 g/dl ) iii . Low serum albumin ( &lt; 3.2 g/dl ) 7 . Patients childbearing potential must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive ; intrauterine device ; male female condom ; diaphragm cervical cap spermicide ; abstinence ) prior randomisation must agree continue use precaution end 140 day safety follow ; 8 . Willing able comply protocol complete study period ; 9 . Willing forego form experimental treatment study ; 10 . Signed date informed consent , prior receipt study medication study related procedure . 11 . ECOG performance status 0 , 1 2 12 . Able complete performance test ( SCP , SMWT , SPPB , HGS ) screen visit two consecutive prerandomisation SMWT result differ 30 % 13 . At least 80 % compliant placebo run period 1 . 1 . Pregnancy lactation screen baseline visit ; 2 . ≥20 % weight loss previous 3 month BMI le 16 kg/m2 3 . Age great 80 less 25 baseline visit ; 4 . Scheduled start new course chemotherapy undergo change present chemotherapeutic regimen dose escalation phase study ( first three week randomisation ) ; 5 . Any surgical procedure within past month plan surgical procedure ; 6 . Any mechanical obstruction alimentary canal ; 7 . Any history evidence intractable vomiting ; 8 . A history clinical evidence hyperthyroidism , cirrhosis , hepatic failure , HIV , renal failure ( determine serum creatinine &gt; 250µmol/l &gt; 2.83 mg/dl screen ) active tuberculosis ( confirm sputum microbiological method , within last five year ) ; 9 . Any physical , medical , socioeconomic noncancer relate cause simple starvation , muscle waste weight loss ; 10 . Receiving enteral tube feed parenteral nutrition screen baseline visit ; 11 . Any clinical evidence ascites significant oedema significant pleural effusion screen baseline visit ; 12 . Current plan treatment 1 . Any oral adrenal corticosteroid ( inhaled topical steroid shortterm use dexamethasone around time chemotherapy acceptable ) ; 2 . Beta adrenergic blocker , 3 . Nondihydropyridine calcium antagonist ( e.g . Verapamil , diltiazem ) , 4 . Alpha adrenergic blocker , 5 . Ivabradine ( Coralan , Procoralan ) , 6 . 5HT agonist antagonist e.g . SSRI 's , , ( shortterm use around time chemotherapy acceptable ) 7 . MAOI 's , 8 . Beta agonist , ( short term onand use inhale bronchodilator acceptable ) 9 . Amiodarone , 10 . Megestrol , Anabolic Steroids prescription medication intend increase appetite treat unintentional weight loss . 13 . Treatment investigational drug therapy within 28 day prior screen visit ; 14 . Previous history administration pindolol spindolol ; 15 . History allergy reaction component MT 102/study drug formulation ; 16 . History presence congestive heart failure ( LVEF &lt; 45 % ) uncontrolled hypertension ( BP &gt; 160/95 mm Hg ) ; 17 . Use pacemaker , implantable defibrillator , internalize metal stent ; 18 . Resting pulse rate le 68 beat per minute high degree conduction defect electrocardiogram ; 19 . A rest supine systolic blood pressure le 100 mm Hg . 20 . A history bronchospasm bronchial asthma ; 21 . History diagnosis brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cachexia</keyword>
	<keyword>Cancer</keyword>
</DOC>